Show simple item record

dc.contributor.authorAtkinson, Lauren Z
dc.contributor.authorColbourne, Lucy
dc.contributor.authorSmith, Alexander L W
dc.contributor.authorHarmer, Catherine J
dc.contributor.authorNobre, Anna C
dc.contributor.authorRendell, Jennifer
dc.contributor.authorJones, Helen
dc.contributor.authorHinds, Christopher
dc.contributor.authorMould, Arne
dc.contributor.authorTunbridge, Elizabeth
dc.contributor.authorCipriani, Andrea
dc.date.accessioned2019-05-09T14:54:39Z
dc.date.available2019-05-09T14:54:39Z
dc.date.issued2019-02
dc.identifier.citationAtkinson, Lauren Z.; Colbourne, Lucy; Smith, Alexander; Harmer, Catherine H.; Nobre, Anna C.; Rendell, Jennifer; Jones, Helen; Hinds, Christopher; Mould, Arne; Tunbridge, Elizabeth; Cipriani, Andrea. The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study. Trials, 2019(20):120en
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/207
dc.descriptionPublished online at: https://doi.org/10.1186/s13063-019-3175-0 Copyright: The Author(s) 2019en
dc.description.abstractBackground: The discovery that voltage-gated calcium channel genes such as CACNA1C are part of the aetiology of psychiatric disorders has rekindled interest in the therapeutic potential of L-type calcium channel (LTCC) antagonists. These drugs, licensed to treat hypertension and angina, have previously been used in bipolar disorder, but without clear results. Neither is much known about the broader effects of these drugs on the brain and behaviour. Methods: The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS) is a high-intensity randomised, double-blind, placebo-controlled experimental medicine study on the effect of the LTCC antagonist nicardipine in healthy young adults with mood instability. An array of cognitive, psychiatric, circadian, physiological, biochemical and neuroimaging (functional magnetic resonance imaging and magnetoencephalography) parameters are measured during a 4-week period, with randomisation to drug or placebo on day 14. We are interested in whether nicardipine affects the stability of these measures, as well as its overall effects. Participants are genotyped for the CACNA1C risk polymorphism rs1006737. Discussion: The results will clarify the potential of LTCC antagonists for repurposing or modification for use in psychiatric disorders in which cognition, mood and sleep are affected.en
dc.description.sponsorshipLC is funded by the Oxford Wellcome Clinical Doctorate Programme. EMT is a Royal Society University Fellow. The research is funded by the Wellcome Trust and supported by the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre. The authors also acknowledge support from the NIHR Oxford cognitive health Clinical Research Facility. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z).en
dc.language.isoenen
dc.subjectBipolar Disorderen
dc.subjectDepressive Disordersen
dc.subjectMood Instabilityen
dc.subjectSleepen
dc.subjectMemoryen
dc.titleThe Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine studyen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record